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is a ligand-activated transcription factor that plays
a critical role in metabolism. Thiazolidinediones,
high-affinity PPARg ligands used clinically to treat
type II diabetes, have been reported to lower blood
pressure and provide other cardiovascular benefits.
Some mutations in PPARg (PPARG) cause type II
diabetes and severe hypertension. Here we tested
the hypothesis that PPARg in vascular muscle plays
a role in the regulation of vascular tone and blood
pressure. Transgenic mice expressing dominant-
negative mutations in PPARg under the control of
a smooth-muscle-specific promoter exhibit a loss of
responsiveness to nitric oxide and striking alterations
in contractility in the aorta, hypertrophy and inward
remodeling in the cerebral microcirculation, and sys-
tolic hypertension. These results identify PPARg as
pivotal in vascular muscle as a regulator of vascular
structure, vascular function, and blood pressure,
potentially explaining some of the cardioprotective
effects of thiazolidinediones.
INTRODUCTION
The incidence of obesity and diabetes and their consequent
cardiovascular sequelae has reached epidemic proportions, jus-
tifying the enormous effort to identify pathways and molecules
involved in their pathogenesis. One molecule that has emerged
at the crossroads of metabolic and cardiovascular diseases is
peroxisome proliferator-activated receptor g (PPARg). PPARg
is a member of the nuclear receptor superfamily of ligand-
activated transcription factors that has a well-recognized role
in regulating metabolic processes. PPARg, which is most highly
expressed in adipose tissue (Chawla et al., 1994), regulates lipid
metabolism in adipocytes (Lehrke and Lazar, 2005) and stimu-
lates adipogenesis (Rosen et al., 1999). The importance of
PPARg in metabolism is underscored by studies reporting insulin
resistance in models lacking PPARg in adipose tissue, skeletalmuscle, or liver (He et al., 2003; Hevener et al., 2003; Matsusue
et al., 2003).
Perhaps themost important observation supporting the signif-
icance of PPARg was the recognition that it is the molecular
target of the thiazolidinedione (TZD) class of insulin sensitizer
drugs used clinically to treat type II non-insulin-dependent dia-
betes mellitus (Lehmann et al., 1995). In animal models, PPARg
activation by TZDs has been shown to have beneficial effects on
cardiovascular endpoints. TZD treatment inhibits early athero-
sclerotic lesion formation in apolipoprotein E- and LDL recep-
tor-deficient mice (Chen et al., 2001; Li et al., 2000), attenuates
the rise in blood pressure (BP) in response to exogenously in-
fused angiotensin II (Diep et al., 2002), and reduces BP and im-
proves vascular function in a normoglycemic model of chronic
hypertension (Ryan et al., 2004). Although there is a substantial
clinical literature reporting the BP-lowering and cardioprotective
effects of TZDs in type II diabetes (Bennett et al., 2004; Dor-
mandy et al., 2005), both have recently been challenged. A re-
cent meta-analysis suggests that the risk of adverse cardiovas-
cular events including myocardial infarction and death may be
increased in patients taking rosiglitazone (Nissen and Wolski,
2007), although this view remains controversial (Singh et al.,
2007). Accordingly, there is an urgent need not only to assess
the beneficial and consequential effects of TZDs but also to un-
derstand the fundamental mechanisms controlling themetabolic
and cardiovascular function of PPARg itself.
The importance of PPARg is corroborated by the severe con-
sequences to individuals carrying certain PPARg (PPARG) muta-
tions. PPARg mutations have been described in patients with
familial partial lipodystrophy and other metabolic disturbances
(Hegele et al., 2002; Savage et al., 2003), and heterozygous car-
riers of the V290M or P467L dominant-negative PPARg muta-
tions exhibit severe early-onset hypertension, insulin resistance,
and type II diabetes (Barroso et al., 1999). The importance of
PPARg in the cardiovascular system is further demonstrated
by the observation that heterozygous knockin mice carrying
one copy of PPARg containing the dominant-negative P465L
mutation (equivalent to human P467L) exhibit abnormal fat distri-
bution and elevated blood pressure (Tsai et al., 2004). Insulin
resistance has been observed in a similar mousemodel express-
ing the P465L mutation on a genetic background of leptin defi-
ciency (Gray et al., 2006).Cell Metabolism 7, 215–226, March 2008 ª2008 Elsevier Inc. 215
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Pivotal Role of PPARg in the VasculaturePPARg is expressed in endothelium and smooth muscle in the
blood vessel wall (Inoue et al., 1998; Marx et al., 1998). Conse-
quently, we hypothesized that the beneficial cardiovascular
effects of TZDs may be mediated by activation of vascular
PPARg and that interference with PPARg’s function by domi-
nant-negative mutations in these cell types may cause vascular
dysfunction and hypertension. We tested the hypothesis that
vascular muscle PPARg is required to mediate vasodilator
signals derived from the endothelium and to regulate vasocon-
strictor mechanisms. We report that mice expressing the domi-
nant-negative P467L or V290M PPARg mutations in vascular
muscle exhibit severely impaired aortic reactivity to endothe-
lium-derived or exogenously applied nitric oxide mechanistically
due to a defect in cGMP-mediated signaling. In addition, there
are marked alterations in vasoconstrictor responses to several
agonists, vascular hypertrophy and remodeling in the microcir-
culation, and systolic hypertension. These changes were due
to the dominant-negative activity imparted by mutant PPARg
since there were no defects in vascular reactivity to vasodilators
or vasoconstrictors in mice expressing wild-type PPARg in vas-
cular muscle. This study provides evidence for a pivotal role of
smooth muscle PPARg in the regulation of vascular structure
and function and provides a molecular explanation for some of
the beneficial cardiovascular effects of TZD drugs.
RESULTS
Analysis of Transgenic Mice Expressing PPARg
Transgenic mice were generated by expressing the protein-cod-
ing sequence of wild-type (WT) human PPARg1 (PPARG) or
PPARg1 carrying either the P467L or the V290M mutation under
the control of the smooth muscle myosin heavy chain promoter
(Figure 1A) (Madsen et al., 1998). These mice are herein termed
S-WT, S-P467L, and S-V290M. Transgenic mice were born at
the expectedMendelian ratio (365 versus 324 for S-P467L trans-
genic versus nontransgenic, respectively; p = 0.29 by c2), and
there was no difference in survival when compared to nontrans-
genic (NT) littermates up to 12 months of age.
RNase protection assays utilizing probes specific for either
mouse (mPPARg) or human (hPPARg) PPARg revealed that the
level of transgene expression in the aorta was elevated com-
pared to endogenous PPARg mRNA (Figure 1B). Transgene
overexpression was also evident in the stomach and uterus,
both of which are rich in smooth muscle (see Figure S1 available
online). Expression of the transgene in S-P467L line 30006/1 was
observed in nearly all tissues tested, consistent with the pres-
ence of blood vessels (Figure 1C). Importantly, however,
whereas hPPARg was primarily overexpressed in tissues high
in smooth muscle content, transgene expression was virtually
undetectable in tissues high in endogenous PPARg such as
white and brown adipose tissue and skeletal muscle
(Figure 1C). Consistent with the absence of transgene expres-
sion in fat and skeletal muscle, there was no difference in body
weight or adipose tissue weight of S-P467L transgenic mice
compared with their NT littermates, nor was there a difference
in levels of fasting blood glucose, fasting plasma insulin, or se-
rum leptin (Table S1). Therefore, expression of dominant-nega-
tive PPARg in vascular smooth muscle did not cause overt sys-
temic metabolic dysfunction. PPARg protein was evident in the216 Cell Metabolism 7, 215–226, March 2008 ª2008 Elsevier Inc.aorta, stomach, and uterus from S-P467L line 30006/1 mice
(Figure 1D).
In situ hybridization was performed to confirm cell-specific
expression of the S-P467L transgene in the aorta (Figure 1E).
Positive staining was observed in the cytoplasm of smooth mus-
cle cells, but not in the endothelium, of S-P467Lmice. There was
no staining with the sense probe, and staining was eliminated in
sections incubated without probe or without the secondary anti-
sera (Figure S2).
Dominant-negative activity of PPARg was verified by examin-
ing expression of two of its target genes, osteopontin (Opn) and
the fatty acid transporter CD36. OPN is a secreted extracellular
matrix protein synthesized by macrophages and endothelial
and smooth muscle cells (Giachelli et al., 1995). Its expression
is decreased upon PPARg activation in THP-1 cells and in whole
aortas of mice treated with rosiglitazone (Oyama et al., 2002).
Consistent with dominant-negative activity, we found signifi-
cantly elevated OPN expression in aortas of S-P467L mice, but
not in aortas of S-WT mice (Figure 1F). CD36 expression is in-
creased in response to PPARg activation (Feng et al., 2000). In
contrast to OPN, we found CD36 expression to be decreased
in S-P467L mice but unaltered in S-WT mice (Figure 1F).
Interference with PPARg Causes Impaired Vasodilation
Endothelial dysfunction is an initial step in the pathogenesis of
many cardiovascular diseases, including hypertension. To deter-
mine the effect of smooth-muscle-specific expression of domi-
nant-negative PPARg on endothelial function, we studied aortas
using vascular rings precontracted with prostaglandin-F2a
(PGF2a) and measured relaxation in response to increasing
doses of acetylcholine (Ach), an endothelium-dependent ago-
nist. The response of S-P467L aortas to Ach was markedly
impaired compared to that of NT littermate aortas (Figure 2A).
Ach stimulates the endothelium to produce nitric oxide (NO)
from endothelial NO synthase (eNOS), which then diffuses to
the vascular muscle to cause relaxation. Since endothelial dys-
function can result from decreased NO bioavailability, we tested
the responsiveness of S-P467L aortas to exogenous NO using
the NO donor sodium nitroprusside (SNP). Like Ach, the vasodi-
lator response of S-P467L aorta to SNP was significantly
impaired (Figure 2B). To determine whether the observed impair-
ment in vascular relaxation was due to generalized smooth
muscle dysfunction, we used the endothelium-independent
and NO-independent vasodilator papaverine (PAP). We ob-
served a slight but statistically significant rightward shift in the
dose-response curve in aortas from S-P467L mice to submaxi-
mal concentrations of PAP (Figure 2C). However, aortas from
S-P467L and NT controls were able to relax completely at max-
imal concentrations of PAP. Although the dose response to PAP
suggests some generalized deficit in smooth muscle function,
this impairment was modest and cannot explain the magnitude
of the impaired response to Ach or SNP.
Importantly, the same impaired response to Ach, SNP, and
PAP was replicated in aortas derived from independent trans-
genic mice expressing the V290M dominant-negative variant of
PPARg, but not aortas derived from mice expressing wild-type
PPARg (Figures 2D–2F). This was verified by comparing
Ach-mediated relaxation in aortas of S-WT mice and a line of
S-P467L mice (30941/2) expressing similar levels of PPARg
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Pivotal Role of PPARg in the VasculatureFigure 1. Transgene Expression in S-PPARg Transgenic Mice
(A) Schematic of the S-PPARg transgenes containing 16 kb of the 50 region of the rat smooth muscle myosin heavy chain (SMMHC) gene including 4 kb of the
promoter, exon 1, 12 kb of intron 1 containing a smooth-muscle-specific enhancer, and an artificial splice acceptor site.
(B) RNase protection assay (RPA) verifying transgene expression in aorta. Probes specific tomouse (m) or human (h) PPARg differentiate endogenous from trans-
genic PPARg expression. Specificity was verified using mouse or human placental (PLAC) RNA.
(C) Representative tissue RPA from S-P467L mice using probes from (B). Tissues include heart (H), lung (Lu), aorta (Ao), right (KR) and left (KL) kidney, adrenal
gland (Ad), liver (Lv), stomach (St), esophagus (Es), testes (Te), epididymis (Ep), white (W) and brown (B) adipose tissue, skeletal muscle (Sk), and brain (Br).
(D) Western blot of tissues from nontransgenic (NT) () and S-P467L (+) mice. ‘‘ns’’ indicates a nonspecific band detected by the secondary antibody even in the
absence of the primary antibody. The PPARg band, indicated by the white arrowhead, was identified both by its size and by its overexpression in 3T3-L1 cells
transfected with CMV-P467L expression vector.
(E) Fluorescence in situ hybridization of sections of thoracic aorta obtained from S-P467L mice and NT littermates. Sections were hybridized with a sense or
antisense RNA probe directed at the unique 30 end of the transgene. Hybridization was visualized using FITC-labeled anti-DIG antibody, and cell nuclei were
visualized using DAPI. L, lumen; A, adventitia. Arrows indicate endothelial cell nuclei.
(F) Opn and CD36 gene expression in aortas of S-WT and S-P467L mice as measured by real-time RT-PCR. *p < 0.05.Cell Metabolism 7, 215–226, March 2008 ª2008 Elsevier Inc. 217
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Pivotal Role of PPARg in the VasculaturemRNA (Figure 1B) and protein in the aorta (Figure S3). This
strongly suggests that the vascular dysfunction observed in
S-P467L and S-V290Mmice is due to dominant-negative activity
imparted by the P467L and V290M mutations in PPARg.
In vascular muscle, NO stimulates soluble guanylate cyclase
(sGC) to produce cGMP. To determine the mechanism causing
the impaired response to NO and to specifically test whether
the impairment is at the level of sGC, we examined the response
of S-P467L aortas to the cGMP analog 8-Br-cGMP. We ob-
served a significant reduction in the relaxation of S-P467L aortas
in response to 8-Br-cGMP (Figure 3A), suggesting that the
PPARg-mediated defect in smooth muscle is downstream of
sGC. cGMP stimulates a series of intracellular signals through
activation of the cGMP-dependent protein kinase (PKG). There
was no change in the relative level of Pkg1 expression in the
aorta between S-P467L andNTmice (Figure 3B). However, there
was an 11.9-fold (p < 0.001) induction in the expression of mRNA
for Pkg2, an isoform of PKG normally found in renal and adrenal
cells but not smooth muscle (Figure 3B). Interestingly, neither
Pkg1 (0.95 ± 0.04) nor Pkg2 (1.0 ± 0.03) mRNA was altered in
aortas from normal C57BL/6 mice in response to the PPARg
agonist rosiglitazone, suggesting that they are not direct targets
of PPARg (unpublished data; see also GEO accession number
Figure 2. Dominant-Negative PPARg
Causes Impaired Vasodilation
(A–C) Isometric tension studies on thoracic aorta
segments of 6- to 8-month-old S-P467L line
30006/1mice (black circle) and their NT littermates
(gray circle) in response to increasing doses of
acetylcholine (Ach) (A), sodium nitroprusside
(SNP) (B), and papaverine (PAP) (C) after aortas
were precontracted with prostaglandin-F2a
(PGF2a) (5–10 mM).
(D–F) Similar studies were performed in S-V290M
line 33068/4 (black diamonds), S-WT line 38667/2
(black squares), and NT mice (gray triangles) in
response to Ach (D), SNP (E), and PAP (F).
*p < 0.05 at the indicated concentration. Error bars
represent SEM.
GSE8949 at http://www.ncbi.nlm.nih.
gov/geo/). This suggests that the signal-
ing defect may lie downstream of PKG,
a hypothesis consistent with the loss of
Ach- and cGMP-mediated relaxation in
PKG1-deficient mice (Pfeifer et al.,
1998). The upregulation of the atypical
isoform may be an attempt, albeit an un-
productive one, to compensate for the
defect in cGMP-dependent signaling in
response to PPARg interference.
Interference with PPARg Causes
Altered Vasoconstriction
The peptide endothelin-1 (ET-1) is an ex-
tremely potent vasoconstrictor released
by the endothelium that is implicated in
many models of hypertension (Schiffrin,
2001). PPARg activation by TZDs has
been shown to inhibit induction of ET-1 expression by thrombin
in endothelial cells (Delerive et al., 1999). Consequently, we
hypothesized that the vasoconstrictor response to ET-1 in aorta
may be augmented in S-P467L mice. ET-1 produces little con-
traction in aortas from normal mice (Figure 4A). Remarkably,
however, we observed a significant hyperresponsiveness (over
7-fold) to the constrictive effect of ET-1 in aortas from S-P467L
mice (Figure 4A). Importantly, a similar effect was observed in
aortas from mice expressing the S-V290M construct
(Figure 4B) and to a lesser extent in a second independent
S-P467L line exhibiting a lower level of transgene expression
(Figure S3). However, there was no enhancement in ET-1-medi-
ated vasoconstriction in mice expressing wild-type PPARg
(Figure 4B; Figure S3), suggesting that the phenotype observed
in S-P467L and S-V290M mice is due to dominant-negative
effects of PPARg.
To examine the mechanism for this hypercontractility, we first
examined which receptor subtype, ETA or ETB, mediated the
ET-1 response. The ETA receptor is mainly expressed in vascular
muscle and is thought to mediate contraction, while the ETB re-
ceptor is expressed both in endothelial cells, where it mediates
relaxation through the production of NO, and in vascular muscle,
where it mediates contraction. We tested the response of these218 Cell Metabolism 7, 215–226, March 2008 ª2008 Elsevier Inc.
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Pivotal Role of PPARg in the VasculatureFigure 3. Mechanism of Impaired Vasodilation in
S-P467L Mice
(A) Isometric tension studies on thoracic aorta segments of
S-P467L line 30006/1mice (blackbars) and theirNT littermates
(gray bars) in response to increasingdoses of the cGMPanalog
8-Br-cGMP. *p < 0.05 at the indicated concentration.
(B) Gene expression of Pkg1 and Pkg2 in aorta, expressed as
S-P467L relative to NT. *p < 0.001.
Error bars represent SEM.vessels in the presence of BQ-123, an ETA receptor antagonist,
and BQ-788, an ETB receptor antagonist. We found that the re-
sponse is primarily mediated by the ETA receptor (Figure 4C).
However, blocking the ETB receptor resulted in slight but signif-
icant inhibition of the contractile response at midrange doses
(Figure 4D). The response to both receptor blockers together
was not different from the response to the ETA blocker alone
(data not shown). ET-1 peptide levels in plasma of S-P467L
mice were unchanged (Figure 4G), whereas in aortas, pre-
proET-1 mRNA levels were reduced by 40% (Figure 4F). At the
receptor level, there was no increase in the level of ETA or ETBreceptor mRNA in the aortas of S-P467L mice (Figure 4F). These
data suggest that the increase in ET-1-mediated contraction is
most likely due to a postreceptor mechanism. Consequently,
we evaluated whether the ET-1 response was dependent upon
Rho kinase activation. The Rho kinase-specific inhibitor
Y27632 had the same inhibitory effect as ETA receptor blockade,
suggesting that the response is dependent upon Rho kinase
activity (Figure 4E).
To further examine the mechanism for the hypercontractile
response to ET-1, we evaluated whether it was due to a general
reprogramming of the vessel wall or was selective for ET-1.Figure 4. Dominant-NegativePPARgCauses
IncreasedContraction in Response to ET-1
(A) Aortic ring studies of S-P467L line 30006/1
mice (black circles) and their NT littermates (gray
circles) were performed in response to increasing
doses of endothelin-1 (ET-1). *p < 0.05 between
transgenic and NT.
(B) The studies in (A) were performed on aortic
segments from NT controls (gray triangles),
S-V290M mice (black diamonds), and S-WT mice
(black squares). *p < 0.05 between transgenic and
NT.
(C–E) The response of S-P467L aortas to ET-1 in
the presence of an ETA receptor antagonist
(1 mmol/l, [C]), an ETB receptor antagonist
(1 mmol/l, [D]), or the Rho kinase inhibitor Y27632
(3 mmol/l, [E]) was determined. **p < 0.05 for antag-
onist versus no antagonist.
(F) Relative gene expression of ETA receptor, ETB
receptor, and preproET-1 mRNA in aorta, ex-
pressed as S-P467L relative to NT. *p < 0.05 versus
NT.
(G) Plasma ET-1 levels in NT (gray bar) and
S-P467L (black bar) mice.
Error bars represent SEM.Cell Metabolism 7, 215–226, March 2008 ª2008 Elsevier Inc. 219
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Pivotal Role of PPARg in the VasculatureAngiotensin II causes minimal contraction in the thoracic and ab-
dominal aorta, and there was no increase in contraction in aortas
from S-P467L mice (data not shown). There was also no differ-
ence in the constrictor response to the receptor-independent
vasoconstrictor potassium chloride (KCl) (Figure 5A) or PGF2a,
the agent used to precontract the vessels prior to Ach and SNP
(Figure 5B). Similar to ET-1, therewas amodest hypercontraction
to serotonin (5-HT) (Figure5C) thatwasalsoobserved inS-V290M
but not S-WT mice (Figure 5D). It is noteworthy that there was
amodest decrease in contraction of the aorta to the a-adrenergic
agonist phenylephrine (PE) in S-P467L mice (Figure 5E). These
data strongly suggest that interferencewithPPARgcauses anag-
onist-selective alteration in vasoconstriction and not a general
reprogramming of the vessel wall to be hypercontractile. Conse-
quently, PPARg regulates vascular tone by modulating a number
of both vasodilator and vasoconstrictor pathways.
Interference with PPARg Causes Systolic Hypertension
One of themain features of patients carrying the V290Mor P467L
PPARg mutation is early-onset hypertension (Barroso et al.,
1999). Therefore, we measured BP of S-P467L and NT littermate
mice using radiotelemetry. The normal diurnal variation in sys-
tolic, mean, and diastolic BP and heart rate (HR) was maintained
in S-P467L and NT mice (Figures 6A–6D). Systolic BP values
Figure 5. Dominant-NegativePPARgCauses
Altered Contraction in Response to Ago-
nists
The contractile response of thoracic aortas to KCl
(A), PGF2a (B), serotonin (5-HT) (C and D), and
phenylephrine (PE) (E) was assessed. In (A)–(C)
and (E), S-P467L mice (black circles) were com-
pared to their NT littermates (gray circles). In (D),
S-V290M (black diamonds), S-WT (black squares)
and NT (gray triangles) mice were examined.
*p < 0.05 for transgenic versus NT. Error bars
represent SEM.
throughout each 24 hr period over 9 con-
secutive days were higher in S-P467L
mice than in NT mice (Figure 6E), whereas
the increase in mean BP was significant
only during the day (Figure 6F). There
was no difference in diastolic BP
(Figure 6G) or in pulse pressure
(Figure 6H). These data suggest the pre-
sentation of isolated systolic hyperten-
sion, a common form of hypertension
observed in the elderly associated with
altered vascular compliance (Wallace
et al., 2007). Interestingly, HR was also
significantly increased in S-P467L mice
(Figures 6D and 6I). To determine whether
this increase in HR was pathological, we
performed echocardiography on S-
P467L and NT mice. There was no differ-
ence in end diastolic or systolic volume,
stroke volume, cardiac output, or ejection
fraction (Table S2), and the ratio of heart
weight to body weight (HW/BW) was unchanged (Figure 6J).
Considering that P467L PPARg was not overexpressed com-
pared to endogenous PPARg in the heart, the increase in HR is
more likely a result of the vascular dysfunction or alterations in
vascular compliance than a result of myocyte dysfunction.
Interference with PPARg Causes Vascular Hypertrophy
and Remodeling
We next examined the structure of cerebral arterioles, resistance
vessels that exhibit hypertrophy and inward remodeling in
response to hypertension. Before deactivation with EDTA, the
diameter of cerebral arterioles was not different between
S-P467L (36 ± 3 mm) and NT (33 ± 4 mm) mice. During maximal
dilation with EDTA, internal diameter was significantly less in
S-P467L cerebral arterioles than in NT cerebral arterioles at all
levels of arteriolar pressure (Figure 7E). While internal and exter-
nal diameter was less, cross-sectional area of the vessel wall
was significantly greater in S-P467L mice (Figures 7A–7C).
Wall thickness was concomitantly increased in S-P467L mice
(Figure 7D). The stress-strain curve in cerebral arterioles in
S-P467L mice was shifted to the right of the curve in NT mice
(Figure 7F). Thus, cerebral arterioles in S-P467L mice undergo
hypertrophy with an increase in distensibility and remodeling
with a reduction in external diameter.220 Cell Metabolism 7, 215–226, March 2008 ª2008 Elsevier Inc.
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Pivotal Role of PPARg in the VasculatureFigure 6. Dominant-Negative PPARg Causes Hypertension
(A–D) Hourly systolic (A), mean (B), and diastolic (C) blood pressure (BP) and heart rate (HR) (D) of S-P467Lmice (black circles, n = 7) and their NT littermates (gray
circles, n = 9) over nine consecutive 24 hr periods were examined. The hourly blood pressure readings for each 60 min period across all 9 days of measurement
were combined to provide the average hourly BP and HR readings.
(E–I) Daytime (6 a.m. to 6 p.m.) and nighttime (6 p.m. to 6 a.m.) averages for systolic (E), mean (F), and diastolic (G) blood pressure; pulse pressure (PP) (H); and
heart rate (I) over 9 days.
(J) Heart weight to body weight (HW/BW) ratio for S-P467L mice (black bar) and their NT littermates (gray bar).
*p < 0.05 versus NT. Error bars represent SEM.DISCUSSION
According to the American Diabetes Association, approximately
65%of diabetic patients will suffer severe cardiovascular conse-
quences such as myocardial infarction and stroke, and as many
as 73% are hypertensive. Thus, gaining an understanding of the
basicmechanisms linkingmetabolic and cardiovascular function
is critical. PPARg has become an extremely attractive candidate,
as it stands at the crossroads of metabolic and cardiovascular
regulation. Although PPARg is expressed in many cardiovascu-
lar tissues, its expression in the endothelium and vascular mus-cle has been of particular interest because of the antihyperten-
sive, antiatherogenic, and anti-inflammatory actions of TZDs
(reviewed in Blaschke et al., 2006). TZDs increase NOS and
decrease ET-1 expression in cultured endothelial cells (Delerive
et al., 1999; Goya et al., 2006). They also decrease proliferation,
migration, and production of fibrotic factors; block calcium
channel activity; and increase insulin receptor signaling in cul-
tured vascular muscle (Nakamura et al., 1998; Pandey et al.,
2007; Gao et al., 2007). With the increasing clinical use of
TZDs as antidiabetesmedications and the plethora of TZD-treat-
ment studies in animals, a protective role for PPARg inCell Metabolism 7, 215–226, March 2008 ª2008 Elsevier Inc. 221
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Pivotal Role of PPARg in the Vasculaturepreventing or diminishing adverse cardiovascular sequelae as-
sociatedwith type II diabetes has emerged. It is particularly note-
worthy that TZDs can lower blood pressure despite promoting
sodium andwater retention by renal tubules (a serious side effect
of TZD drugs), suggesting that their antihypertensive effects are
profound and independent of renal sodium handling.
There has been only one study that has directly interrogated
the specific importance of vascular PPARg in vivo in a manner
that eliminates the PPARg-independent actions of TZDs (Fein-
stein et al., 2005). This was accomplished using mice with Cre-
loxP-mediated endothelium-specific PPARg deficiency (Nicol
et al., 2005). These mice were normotensive at baseline but de-
veloped hypertension after being fed a high-fat diet. Conse-
quently, this finding and a report that individuals carrying domi-
nant-negative mutations in PPARg exhibit severe early-onset
hypertension (Barroso et al., 1999) led us to hypothesize that
the relative importance of PPARg in regulating blood pressure
and vascular tone may be greater in vascular muscle than in
endothelium. We sought to address this concept directly by
interfering with PPARg activity by overexpressing the same
dominant-negative mutations in PPARg that cause hypertension
in humans. Smooth muscle selectivity of the mutant PPARg ex-
pression was achieved by employing the smooth muscle myosin
heavy chain promoter.
Overexpression of P467L PPARg in vascular muscle resulted
in a robust phenotype. Aortas of these animals exhibited a se-
verely impaired response to NO and its downstream mediators.
These findings suggest that the effect exerted by PPARg inter-
ference occurs downstream of soluble guanylate cyclase, per-
haps at the level of or below PKG, the cGMP-dependent protein
kinase. That PKG1 and PKG2 do not appear to be direct targets
of PPARg and that transcription of the atypical isoform of PKG
(PKG2) was markedly increased support the hypothesis that
the deficit may be downstream. Concomitantly, aortas from
these mice exhibited a marked hypercontractile response to
Figure 7. Structural and Mechanical
Changes in Cerebral Arterioles in S-P467L
Mice
(A–D) Internal (A) and external (B) diameter, cross-
sectional area (CSA) of the vessel wall (C), and wall
thickness (D) of cerebral arterioles after maximal
dilation in S-P467L mice (black bars) and their
NT littermates (gray bars).
(E and F) Internal diameter-pressure (E) and
stress-strain (F) relationships in arterioles during
maximal dilation in S-P467L mice (black circles)
and their NT littermates (gray circles). D, cerebral
arteriolar diameter; DO, original arteriolar diameter.
*p < 0.05 versus NT. Error bars represent SEM.
ET-1 that was mediated by the ETA
receptor and dependent upon the Rho
kinase pathway. Again, the defect caus-
ing hypercontraction is likely to be post-
receptor, as there was no difference in
ETA, ETB, or preproET-1mRNA or plasma
ET-1 levels. Hyperresponsiveness to ET-
1 is often seen in vessels in animal
models of hypertension (Miki et al.,
1998). Like ET-1, there was a modest increase in the contractile
response to 5-HT, contraction to which is augmented in hyper-
tension (Watts, 2002). That both ET-1- and 5-HT-mediated con-
traction are increased in vessels from eNOS-deficient (Nos3/)
mice is consistent with these results (Zhou et al., 2006; Budzyn
et al., 2004).
Unlike ET-1 and 5-HT, the contractile responses to KCl, a
receptor-independent vasoconstrictor, and PGF2a, a receptor-
dependent vasoconstrictor, were unaltered whereas the re-
sponse to PE was modestly reduced in aortas from S-P467L
mice. PGF2a was used to precontract aortas prior to treatment
with Ach, SNP, and PAP; therefore, the alteration in vasodilator
responses cannot be accounted for by changes in PGF2a-medi-
ated contraction. While these data suggest that the hypercon-
tractile phenotype in response to ET-1 and 5-HT is selective to
specific agonists and not a generalized change in the vasocon-
strictor state of the vessel, they do not explain the paradoxical
decrease in contraction in response to the a-adrenergic agonist.
Indeed, like ET-1 and 5-HT, PE-induced contractions are aug-
mented in Nos3/ mice (Budzyn et al., 2004). Conversely,
PE-induced contractions are reduced in vessels from rats chron-
ically infused with ET-1, and sensitivity to PE is reduced in ET-
1-infused rats treated with the NOS inhibitor L-NNA (Thorin
et al., 1998). This may be analogous to the S-P467L mice, where
ET-1 responsiveness is increased and NO responsiveness is
severely impaired.
One of the most important findings of this study is that there
was a similar vascular dysfunction in mice overexpressing
another dominant-negative mutation in PPARg (V290M), but
not in mice expressing wild-type PPARg in vascular muscle.
These data suggest that the V290M and P467L mutations act
through a similar interfering mechanism and that the vascular
dysfunction is a result of PPARg interference rather than mere
PPARg overexpression. Moreover, our data suggest that the ex-
tent of vascular impairment seems to be affected by the ‘‘dose’’222 Cell Metabolism 7, 215–226, March 2008 ª2008 Elsevier Inc.
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PPARg have been identified in the DNA-binding and ligand-
binding domains of the protein. The mutations affecting the
DNA-binding domain are thought to retain their interaction with
retinoid X receptor (RXR) and other coactivators but are tran-
scriptionally defective because they cannot bind to the PPARg
response element (PPRE) (Agostini et al., 2006). They may act
dominantly by squelching the availability of RXR or other coacti-
vators, thus preventing their association with normal PPARg. The
ligand-binding domain mutants, including P467L, retain DNA
binding but are transcriptionally defective because themutations
destabilize a region of the protein required for coactivator recruit-
ment in response to ligand binding (Agostini et al., 2004). Current
data suggest that they act dominantly because of increased in-
teractionwith corepressors and reduced cycling of the transcrip-
tion complex on the DNA, presumably preventing the interaction
of the PPREwith normal PPARg/RXR (Li and Leff, 2007). If the re-
duced cycling rate of RXR causes it to be present in limiting
amounts, then both the DNA-binding domain and ligand-binding
domain mutants in PPARg may have far-reaching effects on
other members of the ligand-activated transcription factor family
that interact with RXR. Consequently, we cannot rule out the
possibility that the vascular dysfunction in our model is the result
of such effects, whichmay also occur in human subjects carrying
thesemutations. In addition to the classical transactivation path-
way, PPARg exerts effects on inflammatory genes such as in-
ducible NOS (Nos2) by a more complex ligand-dependent but
PPRE-independent transrepression mechanism (Pascual et al.,
2005). Our observation that dominant-negative PPARg causes
a robust increase in OPN expression suggests that these muta-
tions may also affect this transrepression activity.
Another important finding of this study is the lack of effect of S-
P467L PPARg expression on metabolic parameters, particularly
bodyweight, adipose tissue distribution, and glucose homeosta-
sis. These data suggest that PPARg in smooth muscle does not
affect adipocyte metabolism or whole-body glucose homeosta-
sis. Because expression of dominant-negative PPARg in adi-
pose tissue, skeletal muscle, or liver would have been expected
to produce metabolic disturbances, particularly lipodystrophy
and insulin resistance, the absence of these findings in the
face of severe vascular dysfunction further supports the specific-
ity of our model. As PPARg has recently been reported to mod-
ulate insulin receptor signaling in smooth muscle (Pandey et al.,
2007), future studies will be needed to address whether the
defects observed in the vasculature are limited to the signaling
machinery regulating vasodilation and contraction or whether
there are other cellular metabolic defects as well.
Since PPARg is a transcription factor, the vascular protection
afforded by its ligand-mediated activation most likely results
from a change in the gene expression profile in vascular muscle.
In type II diabetes, administration of TZDs causes increased
PPARg activity, which alters the expression of genes involved
in fatty acid metabolism and glucose utilization, thus resulting
in increased insulin sensitivity. Prevailing evidence indicates
that in the vascular wall, activation of PPARg shifts the balance
from a proinflammatory, proatherogenic, and provasoconstric-
tive state toward an anti-inflammatory, antiatherogenic, and
provasodilatory state. Consequently, during metabolic distur-
bances, endogenous PPARg ligands increase, activating vascu-lar PPARg in an attempt to counterbalance potential damaging
effects. Interfering with PPARg function in the vascular muscle,
as in the mice described herein, prevents this protective effect
from occurring, thus leading to impaired vascular function and
hypertension. In conclusion, the data presented herein provide
strong evidence supporting a critical role for vascular muscle
PPARg in the regulation of vascular tone.
EXPERIMENTAL PROCEDURES
Generation of Transgenic Mice
Generation of the transgene construct is described in Supplemental Experi-
mental Procedures. The transgene was excised, purified, and microinjected
into pronuclei of B6SJLmice (C57BL/6J3SJL/J). Transgenicmiceweremain-
tained by backcross breeding to C57BL/6J. Genotyping was performed by
PCR of tail DNA using the primers 50-TATCTTCTAACTGGGTGGTGGTG-30
and 50-GAGGAGAGTTACTTGGTCGTTCA-30. All mice were fed standard
mouse chow (7013, Teklad Premier Laboratory Diets) and water ad libitum.
Care of the mice used in the experiments met the standards set forth by the
National Institutes of Health (NIH) guidelines for the care and use of experimen-
tal animals. All procedures were approved by the University of Iowa Institu-
tional Animal Care and Use Committee.
RNase Protection Assay
Mouse total RNA was isolated from tissues using TRI Reagent (Molecular Re-
search Center, Inc.) as described by the manufacturer. An RPAIII kit (Ambion)
was used to assay transgenic and endogenous PPARg expression using
cyclophilin (105 nucleotides) as a loading control. Probe construction is de-
tailed in Supplemental Experimental Procedures.
Western Blots
Thirty micrograms of protein was run on a 10% SDS-polyacrylamide gel. Fol-
lowing transfer, the membrane was immunoblotted using serum (1:2000) from
rabbit GN-16,963 immunized with the hPPARg peptide TPHYEDIPFTRTDPVV
ADYKC (Sigma). HRP-conjugated donkey a-rabbit IgG (Santa Cruz) was used
(1:50,000) as a secondary antibody prior to protein detection using an ECL
Plus kit (Amersham Biosciences).
Real-Time RT-PCR
Total aortic RNA was purified using RNeasy spin columns (RNeasy Mini Kit,
QIAGEN) and eluted from the column in 30 ml of DEPC water, and the concen-
tration was established using a NanoDrop ND-1000 (NanoDrop Technologies).
cDNAwas generated by RT-PCR using SuperScript III (Invitrogen) from 400 ng
of total RNA using oligo(dT) priming (18 dT). Reverse transcription was per-
formed at 50C for 2 hr, the enzyme was heat inactivated at 70C for 15 min,
and real-time quantitative PCR (qPCR) was performed using the TaqMan sys-
tem (Applied Biosystems). The equivalent of 10 ng of reverse-transcribed RNA
was PCR amplified using 23 TaqMan Universal PCRMaster Mix (Applied Bio-
systems). Applied Biosystems assay numbers and procedures are provided in
the Supplemental Experimental Procedures.
In Situ Hybridization
Ten micrometer cryosections of thoracic aortas were placed on Superfrost
Plus slides (Fisher Scientific), stored at 80C overnight, and allowed to dry
for 10 min at room temperature (RT) before fixation in 4% paraformaldehyde
for 10 min. The prehybridization mix consisted of 50% deionized formamide,
53 SSC, 40 mg/ml herring sperm DNA (prewarmed at +80C for 5 min), and
103 Denhardt’s solution. Prehybridization was performed in a microwave
(Biowave, Ted Pella) at 45C, 650 Wwith 5 min microwave irradiation followed
by 2 min incubation without irradiation and another 5 min pulse. Hybridization
was carried out using the same mix described above with 0.25 ng/ml of digox-
igenin (DIG)-labeled probe (see Supplemental Experimental Procedures) for
a total amount of 5 ng of probe per section. Posthybridization washes were
performed in a microwave at 250 W (three washes with a 1 min pulse at RT)
in 53 SSC. Stringency washes were performed in 23 SSC at 250 W for
3 min with irradiation, 2 min without irradiation, and 3 min with irradiation
at +50C and 0.53 SSC. The slides were allowed to cool to RT before transferCell Metabolism 7, 215–226, March 2008 ª2008 Elsevier Inc. 223
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ter fish skin gelatin in 13PBS (pH 7.4) for 1 hr at RT before overnight incubation
at 4Cwith sheep anti-DIG (Fab fragments) fluorescein-conjugated antibody at
1:200 (1 mg/ml) (Roche Diagnostics GmbH). The slides were washed six times
(3 min per wash) in PBS at RT and coverslipped under Vectashield with DAPI
(Vector Laboratories) before imaging with a Bio-Rad Radiance 2100 MP con-
focal microscope.
Drugs and Reagents
Ach, SNP, PAP, KCl, 5-HT, PE, BQ-123, and BQ-788 were obtained from
Sigma; 8-Br-cGMP from Fisher Scientific; PGF2a from Pfizer; and Y27632
from Calbiochem. All reagents were dissolved in physiological saline. ET-1
was purchased from Peninsula Laboratories Inc. and dissolved in water.
Plasma ET-1 was determined as described in Supplemental Experimental
Procedures.
Aortic Ring Preparation
Male and female mice 6–8months of age were given a lethal dose of pentobar-
bital (50 mg/mouse intraperitoneally), and the thoracic aorta was quickly re-
moved and placed in Krebs buffer with the following composition (mmol/l):
NaCl 118.3, KCl 4.7, CaCl2 2.5, MgSO4 1.2, KH2PO4 1.2, NaHCO3 25, glucose
11. Connective tissue and adventitial fat were removed, and the vessel was cut
into four equal pieces 4–5 mm in length. Vascular rings were suspended in an
organ bath containing 20 ml Krebs solution maintained at 37C and were con-
nected to a force transducer via steel hooks to measure isometric tension.
Resting tension was increased stepwise to reach 0.5 g, and the rings were al-
lowed to equilibrate for 45 min. After an initial submaximal precontraction
(40%–50% of max) with PGF2a (5–10 mM) and relaxation with Ach (100 mM)
and SNP (100 mM) to establish the functionality of the vessel, dose-response
curves were performed. Vessels were contracted submaximally with PGF2a
and after a stable contraction plateau was reached, dose-response curves
were obtained for Ach (0.01–30 mM), SNP (0.01–30 mM), PAP (1 nM–100 mM),
and 8-Br-cGMP (1–100 mM). Contractile response in the aorta to ET-1
(0.1 nM–0.3 mM), 5-HT (0.01–30 mM), PE (1 nM–30 mM), and KCl (4 mM–
160 mM) was examined. For ET-1 receptor blockade, two aortic rings were
incubated with 1 mM BQ-123, 1 mM BQ-788, or 3 mM Y27632 while the other
two segments were incubated with vehicle for 30 min followed by ET-1.
Data were collected with PowerLab/8SP and analyzed with Chart 5 software
(AD Instruments).
Blood Pressure Analysis
Blood pressure wasmeasured by radiotelemetry as described previously (Lav-
oie et al., 2006). Mice 4–6 months of age were anesthetized with ketamine:
xylazine (87.5 mg:12.5 mg/kg), the catheter (Data Sciences International)
was placed into the left common carotid artery, and the transmitter was placed
subcutaneously along the left flank. Mice were allowed to recover for 10 days,
after which heart rate and arterial pressure were continuously recorded (sam-
pling every 5 min for 10 s intervals) for 9 days. Data were collected and stored
using Dataquest A.R.T. (Data Sciences International).
Measurements of Vascular Structure
Measurements of pressure and diameter in arterioles on the cerebrum were
obtained as described previously (Baumbach et al., 2002) and detailed in Sup-
plemental Experimental Procedures.
Statistical Analysis
All data are expressed as mean ± SEM. Data were excluded only when values
were outside the mean ± 2SD range. Comparisons were made by two-way
repeated-measures ANOVAwith a Tukey’s post hoc test using SigmaStat soft-
ware. Student’s t test was used where appropriate. p < 0.05 was considered
significant.
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